A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung Cancer or Esophageal Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period
Up to the end of follow up visit (4 to 8 weeks)
Bayer Study Director
Study Director
Bayer
United States: Food and Drug Administration
11800
NCT00306137
December 2005
March 2007
Name | Location |
---|---|
Albany, Georgia 31701 | |
Columbia, Missouri 65203 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Austin, Texas 78705 | |
McLean, Virginia 22101 | |
Boston, Massachusetts | |
Charlotte, North Carolina | |
Indianapolis, Indiana | |
Salt Lake City, Utah 84112 |